ArticleScientific reports2025
Serum zonulin level in autistic children and its relation to severity of symptoms a case-control study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Intermittent Fasting andNutrients · 2026Article
- The microbiota-gut-brain axis as a modulator of symptom expression in autism spectrum disorder, with exploratory insights into ADHD: evidence from a structured narrative review on paediatric population.Frontiers in child and adolescent psychiatry · 2026Review
- Neuroinflammatory mechanisms and pharmacological advances in autism spectrum disorder: from inflammatory pathways to targeted interventions.Frontiers in immunology · 2026Review
- Melatonin Improves Intestinal Barrier Impairment in a Mouse Model of Autism Spectrum Disorder.Biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence suggests a possible link between Autism spectrum disorder and gut permeability, specifically as indicated by serum zonulin levels. However, limited studies examine this connection to symptom severity, especially in Egypt. Assessing serum zonulin level in children with autism and its relation to the severity of symptoms. In Mansoura University Hospital's pediatric psychiatry outpatient clinics, case-control research was carried out with children with Autism diagnoses and age- and gender-matched typically developing controls. The Childhood Autism Rating Scale was used to gauge the severity of the symptoms, and the Enzyme-Linked Immunosorbent Assay (ELISA) was used to detect serum zonulin levels. Serum zonulin levels were considerably higher in children with Autism than in the control group (p < 0.05). Additionally, there was a positive correlation between higher zonulin levels and the degree of autism symptoms as determined by CARS scores (r = X, p < 0.05). Children with severe Autism had the highest zonulin levels, according to subgroup analysis, which suggests a possible connection between gut permeability and the intensity of symptoms. This study emphasizes how serum zonulin may serve as a biomarker for intestinal permeability in kids with Autism and how it may be related to the intensity of symptoms. These results highlight the need for more investigation into the gut-brain axis as a potential therapeutic target for Autism. Addressing gut permeability may provide new ways to lessen the intensity of symptoms and enhance results for children with Autism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.